AllSci News
RemeGen adds 5th China indication for HER2 ADC, in urothelial carcinoma
IMPORTANT NOTICE: The source data describes a regulatory approval by China's NMPA — not a regulatory submission or filing. The article below accurately...
Telix partners with Regeneron on radiopharmaceutical therapies in USD 2.1b potential deal
Australia-based Telix Pharmaceuticals Ltd (ASX: TLX, Nasdaq: TLX) and US firm Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced a strategic collaboration to jointly…
FDA accepts Telix's Pixclara resubmission for recurrent or progressive glioma imaging
Telix Pharmaceuticals has submitted a resubmitted New Drug Application (NDA) to the US FDA for Pixclara (floretyrosine F 18), a positron emission tomography...
Almirall expands AI collaboration with Barcelona Supercomputing Center for dermatology
Almirall, S.A. (BME: ALM), a Barcelona-headquartered pharmaceutical company focused on medical dermatology, has announced an expanded collaboration with the Barcelona Supercomputing Center…
Haisco Pharma hands novel pain compound portfolio to AbbVie for USD 745m
A portfolio of novel pain compounds developed by Haisco Pharmaceutical Group (SZSE: 002653) has been licensed exclusively to AbbVie (NYSE: ABBV) under an...
Diamyd considering options after Phase III failure for retogatein in type 1 diabetes
Diamyd Medical (Sweden) has terminated the Phase 3 DIAGNODE-3 trial of retogatein (rhGAD65), an antigen-specific immunotherapy for Stage 3 type 1 diabetes,...
Boehringer, BioNTech collaborate on Phase Ib/II trial for SCLC combination regimen
Boehringer Ingelheim and BioNTech SE (Nasdaq: BNTX) announced a clinical trial collaboration and supply agreement to conduct a Phase Ib/II study evaluating…
Apotex secures first US FDA tentative approval for generic semaglutide
Apotex Corp. has received the first US FDA tentative approval for an Abbreviated New Drug Application (ANDA) for semaglutide injection, referencing Novo…
DualityBio files HER2 ADC trastuzumab pamirtecan for 1st approval in China
DualityBio submits a Biologics License Application (BLA) to China's National Medical Products Administration (NMPA) for trastuzumab pamirtecan (T-Pam;...
GlaxoSmithKline withdraws Wellcovorin from US market after voluntary FDA application withdrawal
GlaxoSmithKline has withdrawn its new drug application for Wellcovorin (leucovorin calcium) tablets from the US FDA, marking the second time the branded…
Oxford BioTherapeutics and Bristol Myers Squibb partner on T-cell engagers for solid tumours
Oxford BioTherapeutics (OBT), a clinical-stage oncology company based in Oxford, UK, announced a multi-year target discovery and development collaboration with Bristol Myers…
Marvel Biosciences secures non-dilutive funding from 5 Horizons Ventures for MB-204 trial
Calgary-based Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF) has secured non-dilutive financial and strategic support from 5 Horizons Ventures to fund...
Annovis Bio closes USD 10m offering to fund Phase III Alzheimer's disease trial
Annovis Bio, Inc. (NYSE: ANVS), a Malvern, Pennsylvania-based clinical-stage company developing oral therapies for neurodegenerative disease, has closed a...
IASO Bio partners with Instituto Butantan on CAR-T cell therapy licensing for Brazil
IASO Biotechnology, headquartered in Shanghai and Nanjing, China, with US operations in Pleasanton, California, has signed a technology licensing agreement with Instituto…
Sino-US biotech Vivatides closes USD 54m Series A for extrahepatic RNA therapeutics
Vivatides Therapeutics, a biotechnology company with operations in Woburn, Massachusetts and Suzhou, China focused on extrahepatic RNA-targeting...
The AllSci Brief
Systematic R&D and deal news. Daily.